A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Who can take part

• Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria:
• Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible
• Manage CSU patients within their practice
• Enrolled in the research network or are referred HCPs who agree to participate
• Have the requisite patient population based on study inclusion/exclusion criteria; Patients eligible for inclusion in this study must meet all of the following criteria:
• ≥ 18 years of age
• Diagnosed with CSU by an HCP
• Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment
• Have access to an electronic device with internet capabilities
• Able to read and understand English
• Willing and able to provide consent for study participation

Who cannot take part

• Exposure to oral corticosteroid treatment in 14 days prior to consent
• Exposure to oral corticosteroid treatment in 14 days prior to initiating treatment with remibrutinib or dupilumab
• Prior participation in a remibrutinib or dupilumab clinical trial
• Cognitive impairment that impacts the patient's ability to participate
• Patients will be excluded if they meet any of the following criteria:
• Unable to procure remibrutinib or dupilumab (through samples, commercially or patient assistance program)